We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+23.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.34B
AUM Growth
+$467M
Cap. Flow
-$99.7M
Cap. Flow %
-2.3%
Top 10 Hldgs %
48.91%
Holding
111
New
4
Increased
17
Reduced
21
Closed
25

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$50.7M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$28.2M
4
IMCR icon
Immunocore
IMCR
+$21.7M
5
AXSM icon
Axsome Therapeutics
AXSM
+$13.2M

Top Sells

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$32.9M
2
QTRX icon
Quanterix
QTRX
+$29.5M
3
VERU icon
Veru
VERU
+$25.1M
4
GMED icon
Globus Medical
GMED
+$22.5M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0.67%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.5B
$337M 7.77%
1,683,362
– –
PTCT icon
2
PTC Therapeutics
PTCT
$6.48B
$282M 6.5%
5,620,580
+575,273
+11% +$28.2M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$378M
$252M 5.81%
15,802,802
– –
TMO icon
4
Thermo Fisher Scientific
TMO
$196B
$221M 5.09%
435,500
– –
IMCR icon
5
Immunocore
IMCR
$1.74B
$209M 4.82%
4,451,483
+455,329
+11% +$21.7M
MASI
6
DELISTED
Masimo
MASI
$203M 4.69%
1,439,993
+89,000
+7% +$13M
RXDX
7
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$188M 4.34%
3,189,605
– –
ARGX icon
8
argenx
ARGX
$53.6B
$165M 3.8%
467,195
+24,560
+6% +$9.1M
PEN icon
9
Penumbra
PEN
$12.5B
$132M 3.05%
698,371
– –
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$131M 3.03%
1,882,663
– –
ESTA icon
11
Establishment Labs
ESTA
$2.77B
$129M 2.98%
2,369,138
– –
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$125M 2.88%
2,574,198
+13,016
+0.5% +$626K
ILMN icon
13
Illumina
ILMN
$28B
$108M 2.48%
580,178
– –
RLMD icon
14
Relmada Therapeutics
RLMD
$529M
$97.9M 2.26%
2,644,475
+6,894
+0.3% +$191K
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.87B
$97.7M 2.25%
2,359,996
+986,712
+72% +$50.7M
NTRA icon
16
Natera
NTRA
$38B
$96.8M 2.23%
2,209,283
+87,000
+4% +$4.14M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.8B
$86.7M 2%
3,084,215
– –
RNAM
18
DELISTED
Avidity Biosciences
RNAM
$84.4M 1.95%
5,170,784
+375,784
+8% +$7.19M
AXSM icon
19
Axsome Therapeutics
AXSM
$11.7B
$84M 1.94%
1,882,164
+263,345
+16% +$13.2M
CUTR
20
DELISTED
Cutera, Inc.
CUTR
$80.7M 1.86%
1,770,400
– –
VCEL icon
21
Vericel Corp
VCEL
$2.36B
$71.9M 1.66%
3,099,904
-423,000
-12% -$11.5M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$65M 1.5%
+3,625,000
New +$47.6M
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
$62.3M 1.44%
884,974
-294,991
-25% -$20.3M
ACET icon
24
Adicet Bio
ACET
$73.9M
$60.3M 1.39%
265,092
+18,137
+7% +$4.6M
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$4.33B
$60.1M 1.38%
3,670,938
-553,171
-13% -$8.96M
1
2 3 4 5

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q3 2022 Portfolio in Review

As of Q3 2022, RTW Investments held 111 positions worth $4.34B, up 12% from $3.87B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

RTW Investments's Q3 2022 filing shows 4 new, 17 increased, 21 reduced and 25 closed positions. Its largest new stake was IVERIC bio, Inc. Common Stock: 3,625,000 shares worth $65M. The largest sale was Tandem Diabetes Care, an estimated $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Industrials.

  • RTW Investments's largest Q3 2022 buy was IVERIC bio, Inc. Common Stock: 3,625,000 shares worth $65M.
  • RTW Investments added most to Ultragenyx Pharmaceutical in Q3 2022, an estimated $50.7M increase.
  • RTW Investments's biggest Q3 2022 reduction was Tandem Diabetes Care, cutting an estimated $32.9M.
  • RTW Investments fully exited Quanterix in Q3 2022, selling an estimated $29.5M.
  • RTW Investments's ten largest holdings make up 49% of its $4.34B portfolio in Q3 2022.
  • RTW Investments opened 4 new positions and closed 25 in Q3 2022.
  • RTW Investments's portfolio value rose 12% quarter-over-quarter to $4.34B.

Based on RTW Investments's 13F filing for Q3 2022, filed 14 Nov 2022.